Canada's Drug Agency says a medication to slow early-stage Alzheimer’s disease should not be covered by public drug plans. Lecanemab has been called the first disease-modifying Alzheimer’s treatment approved for use in Canada, intended to keep people at mild stages of the disease for longer. Katherine Ward has this story and more in Health Matters for Feb. 20, 2026.